Pneumococcal Vaccine, Polyvalent (23-valent)

BIOLOGICAL5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC

Conditions

HIV InfectionsHepatitis BMeaslesPertussisPneumococcal InfectionPneumococcal Infections

Phase 1

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

CompletedNCT00000829

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Pneumococcal Infections

End: 1999-10-31Target: 60Updated: 2021-10-28

Phase 3

Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)

CompletedNCT00496093

Merck Sharp & Dohme LLCPneumococcal Infection

Start: 2005-10-31End: 2006-01-31Updated: 2017-03-14

Unknown Phase

Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

WithdrawnNCT00001080

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Updated: 2021-11-01

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

CompletedNCT00013871

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis B, HIV Infections, Measles +2

End: 2004-11-30Target: 300Updated: 2021-11-01

Study of Anti-HIV Therapy Intensification

CompletedNCT00034086

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2006-06-30Target: 22Updated: 2012-05-18

Related Papers

Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy.

2012-06-1231 citations